Scarica l'app Stockscreener
1.60
5.26%
0.08
Dopo l'orario di chiusura:
1.59
-0.01
-0.63%
Precedente Chiudi:
$1.52
Aprire:
$1.49
Volume 24 ore:
311.07K
Relative Volume:
1.09
Capitalizzazione di mercato:
$56.84M
Reddito:
-
Utile/perdita netta:
$-31.39M
Rapporto P/E:
-1.9048
EPS:
-0.84
Flusso di cassa netto:
$-18.45M
1 W Prestazione:
+0.00%
1M Prestazione:
+50.94%
6M Prestazione:
-14.89%
1 anno Prestazione:
+116.95%
Intervallo 1D:
$1.48
$1.6669
Intervallo di 1 settimana:
$1.43
$1.68
Portata 52W:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Nome
Quince Therapeutics Inc
Settore
Industria
Telefono
415-910-5717
Indirizzo
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Confronta QNCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.60 | 56.84M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-24 | Iniziato | Oppenheimer | Outperform |
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - BioSpace
Quince Therapeutics announces closing of up to $22 million private placement of securities - MarketScreener
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities | QNCX Stock News - GuruFocus
June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st
D. Boral Capital Reaffirms Buy Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Two Sigma Investments LP Takes $57,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics (QNCX) Analyst Rating Update: Buy Rating Mai - GuruFocus
Quince Therapeutics Raises $11.5M in Private Placement - TipRanks
Quince Therapeutics Announces Pricing of Up to $22 Million Priva - GuruFocus
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - BioSpace
Quince Therapeutics (QNCX) Secures $11.5 Million Through New Sec - GuruFocus
Quince Therapeutics (QNCX) Secures $11.5M Through Private Placem - GuruFocus
Quince Therapeutics (QNCX) Secures $11.5 Million Through New Securities Agreement | QNCX Stock News - GuruFocus
Quince Therapeutics Prices $22 Million Private Placement of Shares, Warrants - marketscreener.com
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities | QNCX Stock News - GuruFocus
Quince Therapeutics Announces Pricing Of Up To $22 Mln Private Placement Of Securities - marketscreener.com
Quince Therapeutics stock soars after announcing $11.5 million private placement - Investing.com Nigeria
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA) - The Globe and Mail
Quince Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Transcript : Quince Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Shares Acquired by Northern Trust Corp - Defense World
Quince Therapeutics (QNCX) Stock Rating and Price Target Update - GuruFocus
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - BioSpace
Quince Therapeutics Says Enrollment for Phase 3 Clinical Trial in Ataxia-Telangiectasia Exceeds 75% - marketscreener.com
Quince Therapeutics (QNCX) Phase 3 Trial Achieves Major Progress - GuruFocus
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NE - GuruFocus
Quince Therapeutics (QNCX) Phase 3 Trial Achieves Major Progress in Enrollment | QNCX Stock News - GuruFocus
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 42.9% in May - Defense World
FY2025 Earnings Forecast for TSE:WEE Issued By Roth Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 7% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison - Defense World
Brookline Capital Management Forecasts QNCX Q2 Earnings - Defense World
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics Reports Q1 2025 Results and Strategic Updates - TipRanks
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - BioSpace
Quince Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quince Therapeutics, Inc. SEC 10-Q Report - TradingView
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results | QNCX Stock News - GuruFocus
QNCXQuince Latest Stock News & Market Updates - Stock Titan
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Confe - GuruFocus
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Conference - GuruFocus
Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics Inc Azioni (QNCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quince Therapeutics Inc Azioni (QNCX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):